Niranjan Awasthi1, Margaret A Schwarz, Roderich E Schwarz. 1. Division of Surgical Oncology, Department of Surgery, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390-8548, USA.
Abstract
BACKGROUND: Gemcitabine (Gem) has limited clinical benefits in pancreatic ductal adenocarcinoma (PDAC). Sunitinib (Su) is a novel, multi-target receptor tyrosine kinase inhibitor that has antitumour activities. This study tested the benefits of combined gemcitabine and sunitinib in PDAC. METHODS: Cell viability and protein expression were evaluated by WST-1 assay and Western blotting. Tumour growth and survival experiments were performed in murine xenografts. RESULTS: In PDAC cells, Gem, Su and Su + Gem, respectively, caused 28%, 22% and 48% inhibition in proliferation at 100 nM. In endothelial cells, Gem, Su and Su + Gem, respectively, caused 49%, 32% and 72% inhibition in proliferation. In fibroblasts, Gem, Su and Su + Gem, respectively, caused 65%, 14% and 79% inhibition in proliferation. Su increased apoptosis, as evidenced by the cleavage of caspase-3 and PARP-1 proteins. Net tumour growth compared with controls in the Gem, Su and Su + Gem groups was 57%, 6% and 1%, respectively. Intratumoral proliferative activity was reduced by 33%, 82% and 75% in the Gem, Su and Su + Gem groups, respectively, compared with controls. Median survival in the control, Su, Gem and Su + Gem groups was 16, 21, 24 and 30 days, respectively (P=0.007). CONCLUSIONS: These findings support a combination approach using multi-target antiangiogenic agents such as sunitinib with standard gemcitabine therapy in the treatment of PDAC.
BACKGROUND:Gemcitabine (Gem) has limited clinical benefits in pancreatic ductal adenocarcinoma (PDAC). Sunitinib (Su) is a novel, multi-target receptor tyrosine kinase inhibitor that has antitumour activities. This study tested the benefits of combined gemcitabine and sunitinib in PDAC. METHODS: Cell viability and protein expression were evaluated by WST-1 assay and Western blotting. Tumour growth and survival experiments were performed in murine xenografts. RESULTS: In PDAC cells, Gem, Su and Su + Gem, respectively, caused 28%, 22% and 48% inhibition in proliferation at 100 nM. In endothelial cells, Gem, Su and Su + Gem, respectively, caused 49%, 32% and 72% inhibition in proliferation. In fibroblasts, Gem, Su and Su + Gem, respectively, caused 65%, 14% and 79% inhibition in proliferation. Su increased apoptosis, as evidenced by the cleavage of caspase-3 and PARP-1 proteins. Net tumour growth compared with controls in the Gem, Su and Su + Gem groups was 57%, 6% and 1%, respectively. Intratumoral proliferative activity was reduced by 33%, 82% and 75% in the Gem, Su and Su + Gem groups, respectively, compared with controls. Median survival in the control, Su, Gem and Su + Gem groups was 16, 21, 24 and 30 days, respectively (P=0.007). CONCLUSIONS: These findings support a combination approach using multi-target antiangiogenic agents such as sunitinib with standard gemcitabine therapy in the treatment of PDAC.
Authors: H A Burris; M J Moore; J Andersen; M R Green; M L Rothenberg; M R Modiano; M C Cripps; R K Portenoy; A M Storniolo; P Tarassoff; R Nelson; F A Dorr; C D Stephens; D D Von Hoff Journal: J Clin Oncol Date: 1997-06 Impact factor: 44.544
Authors: Carmen C Solorzano; Rosa Hwang; Cheryl H Baker; Corazon D Bucana; Peter W Pisters; Douglas B Evans; Jerald J Killion; Isaiah J Fidler Journal: Clin Cancer Res Date: 2003-05 Impact factor: 12.531
Authors: Dirk B Mendel; A Douglas Laird; Xiaohua Xin; Sharianne G Louie; James G Christensen; Guangmin Li; Randall E Schreck; Tinya J Abrams; Theresa J Ngai; Leslie B Lee; Lesley J Murray; Jeremy Carver; Emily Chan; Katherine G Moss; Joshua O Haznedar; Juthamas Sukbuntherng; Robert A Blake; Li Sun; Cho Tang; Todd Miller; Sheri Shirazian; Gerald McMahon; Julie M Cherrington Journal: Clin Cancer Res Date: 2003-01 Impact factor: 12.531
Authors: Anne-Marie O'Farrell; Tinya J Abrams; Helene A Yuen; Theresa J Ngai; Sharianne G Louie; Kevin W H Yee; Lily M Wong; Weiru Hong; Leslie B Lee; Ajia Town; Beverly D Smolich; William C Manning; Lesley J Murray; Michael C Heinrich; Julie M Cherrington Journal: Blood Date: 2003-01-16 Impact factor: 22.113
Authors: Jordan D Berlin; Paul Catalano; James P Thomas; John W Kugler; Daniel G Haller; Al Bowen Benson Journal: J Clin Oncol Date: 2002-08-01 Impact factor: 44.544
Authors: K Fujimoto; R Hosotani; M Wada; J U Lee; T Koshiba; Y Miyamoto; S Tsuji; S Nakajima; R Doi; M Imamura Journal: Eur J Cancer Date: 1998-08 Impact factor: 9.162
Authors: Caio M Rocha Lima; Mark R Green; Robert Rotche; Wilson H Miller; G Mark Jeffrey; Laura A Cisar; Adele Morganti; Nicoletta Orlando; Gabriela Gruia; Langdon L Miller Journal: J Clin Oncol Date: 2004-09-15 Impact factor: 44.544
Authors: Kate Crawford; Erin Bontrager; Margaret A Schwarz; Apurva Chaturvedi; Daniel D Lee; Hassan Md Sazzad; Urs von Holzen; Changhua Zhang; Roderich E Schwarz; Niranjan Awasthi Journal: Cancer Biol Ther Date: 2021-12-09 Impact factor: 4.742
Authors: Joanna M Brell; Smitha S Krishnamurthi; Linda Rath; Joseph A Bokar; Panayiotis Savvides; Joseph Gibbons; Matthew M Cooney; Neal J Meropol; Percy Ivy; Afshin Dowlati Journal: Cancer Chemother Pharmacol Date: 2012-08-07 Impact factor: 3.333
Authors: Eric Pion; Julia Karnosky; Sofie Boscheck; Benedikt J Wagner; Katharina M Schmidt; Stefan M Brunner; Hans J Schlitt; Thiha Aung; Christina Hackl; Silke Haerteis Journal: Cancers (Basel) Date: 2022-07-31 Impact factor: 6.575